Journal
CELLS
Volume 12, Issue 17, Pages -Publisher
MDPI
DOI: 10.3390/cells12172146
Keywords
sarcopenic obesity; obesity; sarcopenia; energy expenditure; insulin resistance; muscle protein degradation; GABA
Categories
Ask authors/readers for more resources
Sarcopenic obesity, characterized by obesity and muscle wasting, is common in the elderly and has become an increasing public health burden. This condition has a greater impact on metabolic disease compared to obesity or sarcopenia alone. The underlying mechanisms of sarcopenic obesity are complex and not fully understood, highlighting the need for effective treatments. This study investigates the potential therapeutic use of Gamma-aminobutyric acid (GABA) in preventing age-related sarcopenic obesity and related metabolic diseases.
Sarcopenic obesity is characterized by concurrent obesity and muscle wasting (sarcopenia) and is common in the elderly. Sarcopenic obesity has steadily increased as the aging population has grown and is an increasing public health burden. Both obesity and sarcopenia independently increase health risks of the elderly, but sarcopenic obesity has a greater effect on metabolic disease than either obesity or sarcopenia alone. The metabolic mechanisms of obesity and sarcopenia are strongly interconnected, and obesity and sarcopenia form a vicious cycle, with each pathology exacerbating the other. The pathogenesis of sarcopenic obesity is more complex than either disease alone and remains incompletely understood, underscoring the significant unmet clinical need for effective sarcopenic obesity treatments. We aimed to determine the efficacy and underlying regulatory mechanisms of Gamma-aminobutyric acid (GABA) in sarcopenic obesity in high-fat-diet-fed obese aged mice and alterations in related mechanisms to determine the potential of GABA as a therapeutic modality for sarcopenic obesity. In this study, we used young (3 months) and aged (20 months) mice to evaluate age-related sarcopenic obesity. The daily administration of GABA for 8 weeks resulted in decreased fat mass and increased muscle mass and strength in aged mice. GABA also enhanced energy expenditure in both adipose tissue and skeletal muscle. In addition, GABA promoted muscle synthesis and decreased muscle degradation by activating the phosphatidylinositol-3-kinase (PI3K)/Akt pathway. These findings demonstrate that GABA has potential uses in preventing age-related sarcopenic obesity and related metabolic diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available